1. An agent composed of edaravone and dexborneol2. Intravenous injection3. To evaluate the effect of Edaravone and Dexborneol Concentrated Solution for Injection on the levels of IL-8, TNF-α and il-1β in the peripheral blood of ALS patients.4. To evaluate the efficacy and safety of Edaravone and Dexborneol Concentrated Solution for Injection in the treatment of ALS.5. Enrollment number: 30. This evidence concerns the gene CXCL8 and amyotrophic lateral sclerosis.